The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen

OBJECTIVE: Bortezomib is one of the important drugs that have made breakthrough progress in multiple myeloma (MM) in the past 10 years. However, the heterogeneity of its efficacy makes it difficult to predict the risk of disease progression. The purpose of this study is to determine the prognostic s...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Front Oncol
Κύριοι συγγραφείς: Pang, Yanbin, Shao, Hong, Yang, Ziheng, Fan, Lixia, Liu, Wenwen, Shi, Jianhong, Wang, Yuqing, Han, Ying, Yang, Lin
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Frontiers Media S.A. 2020
Θέματα:
Oncology
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7492571/
https://ncbi.nlm.nih.gov/pubmed/32984029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01617
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια